Format

Send to

Choose Destination
J Diabetes Complications. 2015 Jan-Feb;29(1):146-56. doi: 10.1016/j.jdiacomp.2014.08.008. Epub 2014 Aug 28.

From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy.

Author information

1
Institute for Clinical Diabetology, German Diabetes Center at Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; Department of Endocrinology and Diabetology, University Hospital, Düsseldorf, Germany. Electronic address: dan.ziegler@ddz.uni-duesseldorf.de.
2
Section of Endocrinology, Tulane University Medical Center, New Orleans LA, USA.

Abstract

Painful diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus, affecting, by some estimates, up to one quarter of diabetic patients. Since 2010, no fewer than 5 major international treatment guidelines for painful DPN have been issued, and there are meaningful differences among them. Duloxetine, pregabalin, gabapentin, and tricyclic antidepressants are the mainstays of treatment, but the choice of which class or agent to use in any given patient should be informed by patient characteristics. This review seeks to describe the differences among the recently issued guidelines, to assess the evidence on which they are based, and to offer insight into the most appropriate treatment choices based on patient characteristics.

KEYWORDS:

Anticonvulsants; Antidepressants; Opioids; Painful diabetic neuropathy; Pharmacologic therapy; Treatment guidelines

PMID:
25239450
DOI:
10.1016/j.jdiacomp.2014.08.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center